Trillium Therapeutics Stock Forecast, Price & News

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

Is Trillium Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Trillium Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares.
View analyst ratings for Trillium Therapeutics or view top-rated stocks.

How has Trillium Therapeutics' stock been impacted by Coronavirus?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 255.3% and is now trading at $18.44.
View which stocks have been most impacted by COVID-19.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Trillium Therapeutics.

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its quarterly earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01.
View Trillium Therapeutics' earnings history.

What price target have analysts set for TRIL?

6 analysts have issued 12 month price targets for Trillium Therapeutics' shares. Their forecasts range from $18.50 to $25.00. On average, they expect Trillium Therapeutics' stock price to reach $20.30 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for Trillium Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:

• Jan Skvarka, President, Chief Executive Officer & Director
• James T. Parsons, Chief Financial Officer
• Robert A. Uger, Chief Scientific Officer
• Kathleen Large, Senior Vice President-Clinical Operations
• Ingmar Bruns, Chief Medical Officer

Who are some of Trillium Therapeutics' key competitors?

Some companies that are related to Trillium Therapeutics include Jazz Pharmaceuticals (JAZZ), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Grifols (GRFS), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Sarepta Therapeutics (SRPT), Zai Lab (ZLAB), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE) and Perrigo (PRGO).
View all of TRIL's competitors.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Who are Trillium Therapeutics' major shareholders?

Trillium Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.82%), Magnetar Financial LLC (3.12%), Omni Partners US LLC (2.25%), Versor Investments LP (1.84%), Gabelli Funds LLC (1.71%) and Westchester Capital Management LLC (1.52%). Company insiders that own Trillium Therapeutics stock include James T Parsons, Jan Skvarka, Penka Petrova and Robert Uger.
View institutional ownership trends for Trillium Therapeutics.

Which major investors are selling Trillium Therapeutics stock?

TRIL stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Connor Clark & Lunn Investment Management Ltd., Marshall Wace LLP, TD Asset Management Inc., The Manufacturers Life Insurance Company , and California State Teachers Retirement System. Company insiders that have sold Trillium Therapeutics company stock in the last year include James T Parsons, Jan Skvarka, Penka Petrova, and Robert Uger.
View insider buying and selling activity for Trillium Therapeutics or view top insider-selling stocks.

Which major investors are buying Trillium Therapeutics stock?

TRIL stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Omni Partners US LLC, Versor Investments LP, Westchester Capital Management LLC, Gabelli Funds LLC, CNH Partners LLC, Alpine Associates Management Inc., and Segantii Capital Management Ltd.
View insider buying and selling activity for Trillium Therapeutics or or view top insider-buying stocks.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $18.44.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of $1.94 billion and generates $150 thousand in revenue each year. The biotechnology company earns $-59.35 million in net income (profit) each year or $0.62 on an earnings per share basis.

How many employees does Trillium Therapeutics have?

Trillium Therapeutics employs 33 workers across the globe.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected].